336 related articles for article (PubMed ID: 19397468)
1. Nephrogenic diabetes insipidus induced by two amphotericin B liposomal formulations.
Metzger NL; Varney Gill KL
Pharmacotherapy; 2009 May; 29(5):613-20. PubMed ID: 19397468
[TBL] [Abstract][Full Text] [Related]
2. Possible liposomal amphotericin B-induced nephrogenic diabetes insipidus.
Canada TW; Weavind LM; Augustin KM
Ann Pharmacother; 2003 Jan; 37(1):70-3. PubMed ID: 12503936
[TBL] [Abstract][Full Text] [Related]
3. Treatment of invasive fungal sinusitis with liposomal amphotericin B: a report of four cases.
Sungkanuparph S; Sathapatayavongs B; Kunachak S; Luxameechanporn T; Cheewaruangroj W
J Med Assoc Thai; 2001 Apr; 84(4):593-601. PubMed ID: 11460976
[TBL] [Abstract][Full Text] [Related]
4. Successful use of liposomal amphotericin B in a case of amphotericin B-induced nephrogenic diabetes insipidus.
Späth-Schwalbe E; Koschuth A; Dietzmann A; Schanz J; Possinger K
Clin Infect Dis; 1999 Mar; 28(3):680-1. PubMed ID: 10194097
[No Abstract] [Full Text] [Related]
5. Amphotericin B-induced partial nephrogenic diabetes insipidus in a child.
Hopp L; Bernardi J; Reeves G
Pediatr Nephrol; 2001 Jul; 16(7):594-7. PubMed ID: 11465810
[TBL] [Abstract][Full Text] [Related]
6. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial).
Cornely OA; Maertens J; Bresnik M; Ebrahimi R; Ullmann AJ; Bouza E; Heussel CP; Lortholary O; Rieger C; Boehme A; Aoun M; Horst HA; Thiebaut A; Ruhnke M; Reichert D; Vianelli N; Krause SW; Olavarria E; Herbrecht R;
Clin Infect Dis; 2007 May; 44(10):1289-97. PubMed ID: 17443465
[TBL] [Abstract][Full Text] [Related]
7. Combined renal tubular acidosis and diabetes insipidus in hematological disease.
Hoorn EJ; Zietse R
Nat Clin Pract Nephrol; 2007 Mar; 3(3):171-5. PubMed ID: 17322929
[TBL] [Abstract][Full Text] [Related]
8. [Remission of invasive sinusal and pulmonary aspergillosis with liposomal amphotericin B in a patient with chronic lymphatic leukemia following failure with conventional amphotericin].
Palacio C; Acebedo G; López A; Jodar JM
Sangre (Barc); 1994 Oct; 39(5):389-92. PubMed ID: 7754445
[TBL] [Abstract][Full Text] [Related]
9. Chest discomfort associated with liposomal amphotericin B: report of three cases and review of the literature.
Johnson MD; Drew RH; Perfect JR
Pharmacotherapy; 1998; 18(5):1053-61. PubMed ID: 9758315
[TBL] [Abstract][Full Text] [Related]
10. Toxicity, stability and pharmacokinetics of amphotericin B in immunomodulator tuftsin-bearing liposomes in a murine model.
Khan MA; Owais M
J Antimicrob Chemother; 2006 Jul; 58(1):125-32. PubMed ID: 16709592
[TBL] [Abstract][Full Text] [Related]
11. What is the current and future status of conventional amphotericin B?
Kleinberg M
Int J Antimicrob Agents; 2006 Jun; 27 Suppl 1():12-6. PubMed ID: 16707251
[TBL] [Abstract][Full Text] [Related]
12. Amphotericin B use in children: conventional and lipid-based formulations.
Kuyucu N
Expert Rev Anti Infect Ther; 2011 Mar; 9(3):357-67. PubMed ID: 21417875
[TBL] [Abstract][Full Text] [Related]
13. [Liposomal amphotericin B in the treatment of severe fungal infections. Results of a clinical cohort trial].
Rieger CT; Dittmer M; Ostermann H
Dtsch Med Wochenschr; 2007 Oct; 132(40):2062-6. PubMed ID: 17899499
[TBL] [Abstract][Full Text] [Related]
14. Liposomal amphotericin B for the treatment of severe fungal infection.
Michaud D
Dynamics; 2001; 12(1):17-21. PubMed ID: 11982230
[TBL] [Abstract][Full Text] [Related]
15. Amphotericin B-induced nephrogenic diabetes insipidus in a case of cryptococcemia.
Fujita Y; Kasahara K; Uno K; Konishi M; Maeda K; Yoshimoto E; Murakawa K; Mikasa K; Amano I; Morii T; Kimura H
Intern Med; 2005 May; 44(5):458-61. PubMed ID: 15942094
[TBL] [Abstract][Full Text] [Related]
16. Lipid formulations of amphotericin B.
Dix SP; Andriole VT
Curr Clin Top Infect Dis; 2000; 20():1-23. PubMed ID: 10943516
[TBL] [Abstract][Full Text] [Related]
17. [Safety of liposomal amphotericin B in patients with high risk of nephrotoxicity].
González E; Rada MA; Lumbreras C; Ramos JT; Aguado JM
Enferm Infecc Microbiol Clin; 2000 Apr; 18(4):162-4. PubMed ID: 10932392
[TBL] [Abstract][Full Text] [Related]
18. Vasopressin-resistant nephrogenic diabetes insipidus. A result of amphotericin B therapy.
Barbour GL; Straub KD; O'Neal BL; Leatherman JW
Arch Intern Med; 1979 Jan; 139(1):86-8. PubMed ID: 760689
[TBL] [Abstract][Full Text] [Related]
19. Aerosolized liposomal amphotericin B for the prevention of invasive pulmonary aspergillosis during prolonged neutropenia: a randomized, placebo-controlled trial.
Rijnders BJ; Cornelissen JJ; Slobbe L; Becker MJ; Doorduijn JK; Hop WC; Ruijgrok EJ; Löwenberg B; Vulto A; Lugtenburg PJ; de Marie S
Clin Infect Dis; 2008 May; 46(9):1401-8. PubMed ID: 18419443
[TBL] [Abstract][Full Text] [Related]
20. Micafungin versus liposomal amphotericin B for pediatric patients with invasive candidiasis: substudy of a randomized double-blind trial.
Queiroz-Telles F; Berezin E; Leverger G; Freire A; van der Vyver A; Chotpitayasunondh T; Konja J; Diekmann-Berndt H; Koblinger S; Groll AH; Arrieta A;
Pediatr Infect Dis J; 2008 Sep; 27(9):820-6. PubMed ID: 18679151
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
